ASX Announcement

Starpharma receives $7.1M R&D tax incentive refund

Melbourne, Australia; 23 December 2022: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announces it has received a $7.1M research and development (R&D) tax incentive refund under the Australian Federal Government's R&D Tax Incentive scheme.

The tax refund relates to Starpharma's Australian and international R&D expenses from the 2022 financial year for eligible R&D activities across Starpharma's portfolio.

Dr Jackie Fairley, CEO of Starpharma, commented: "The Australian Government's R&D Tax Incentive plays a key role in helping local companies continue to innovate and grow. Starpharma has developed three clinical stage DEP® assets with high commercial and therapeutic potential as well as a portfolio of marketed products including VIRALEZE™, a novel broad-spectrum antiviral nasal spray."

The Australian Federal Government's R&D Tax Incentive scheme offers a tax offset for entities which conduct eligible R&D activities to drive innovation and investment in Australia's economy. Investing in scientific and medical R&D supports high value, knowledge-based jobs and contributes substantially to the Australian economy and also supports companies in solving important health challenges.

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for DEP® drug delivery, respiratory viruses and VivaGel®.

Starpharma's proprietary drug delivery platform technology, DEP®, is being used to improve pharmaceuticals to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies.

DEP® partnerships include oncology programs with AstraZeneca, with MSD in the area of Antibody Drug Conjugates (ADCs), with Chase Syn in the area of anti-infectives, and with other world leading pharmaceutical companies. Partnered DEP® programs have the potential to generate significant future milestones and royalties.

Starpharma has developed VIRALEZE™, an antiviral nasal spray that is registered in a number of countries, including in Europe and the UK. VIRALEZE™ is not approved for use or supply in Australia. SPL7013 is also utilised in the following products: VivaGel® condom and VivaGel® BV. VivaGel® products have been licensed in >160 countries and are registered in >45 countries, including the in UK, in Europe, Japan, in Southeast Asia, South Africa, Australia, and New Zealand.

Starpharma.com | Twitter | LinkedIn

Media: Sumit Media
Grant Titmus
Mob: +61 419 388 161
grant@sumitmedia.com.au

Starpharma Holdings Limited
Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure
This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.

Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.